OBJECTIVE: Positron emission tomography (PET) studies performed with [(11) C]raclopride have consistently reported lower binding to D(2/3) receptors and lower amphetamine-induced dopamine (DA) release in cocaine abusers relative to healthy controls. A limitation of these studies that were performed with D(2/3) antagonist radiotracers such as [(11) C]raclopride is the failure to provide information that is specific to D(2/3) receptors configured in a state of high affinity for the agonists (i.e., D(2/3) receptors coupled to G-proteins, D(2/3 HIGH) ). As the endogenous agonist DA binds with preference to D(2/3 HIGH) relative to D(2/3 LOW) receptors (i.e., D(2/3) receptors uncoupled to G-proteins) it is critical to understand the in vivo status of D(2/3 HIGH) receptors in cocaine dependence. Thus, we measured the available fraction of D(2/3) (HIGH) receptors in 10 recently abstinent cocaine abusers (CD) and matched healthy controls (HC) with the D(2/3) antagonist and agonist PET radiotracers [(11) C]raclopride and [(11) C]NPA. METHODS: [(11) C]raclopride and [(11) C]NPA binding potential (BP) (BP(ND) ) in the striatum were measured with kinetic analysis using the arterial input function. The available fraction of D(2/3 HIGH) receptors, i.e., % R(HIGH) available = D(2/3 HIGH) /(D(2/3 HIGH) + D(2/3 LOW) ) was then computed as the ratio of [(11) C]NPA BP(ND) /[(11) C]raclopride BP(ND) . RESULTS: No differences in striatal [(11) C]NPA BP(ND) (HC = 1.00 ± 0.17; CD = 0.97 ± 0.17, P = 0.67) or available % R(HIGH) (HC = 39% ± 5%; CD = 41% ± 5%, P = 0.50) was observed between cocaine abusers and matched controls. CONCLUSIONS: The results of this [(11) C]NPA PET study do not support alterations in D(2/3 HIGH) binding in the striatum in cocaine dependence.
OBJECTIVE: Positron emission tomography (PET) studies performed with [(11) C]raclopride have consistently reported lower binding to D(2/3) receptors and lower amphetamine-induced dopamine (DA) release in cocaine abusers relative to healthy controls. A limitation of these studies that were performed with D(2/3) antagonist radiotracers such as [(11) C]raclopride is the failure to provide information that is specific to D(2/3) receptors configured in a state of high affinity for the agonists (i.e., D(2/3) receptors coupled to G-proteins, D(2/3 HIGH) ). As the endogenous agonist DA binds with preference to D(2/3 HIGH) relative to D(2/3 LOW) receptors (i.e., D(2/3) receptors uncoupled to G-proteins) it is critical to understand the in vivo status of D(2/3 HIGH) receptors in cocaine dependence. Thus, we measured the available fraction of D(2/3) (HIGH) receptors in 10 recently abstinent cocaine abusers (CD) and matched healthy controls (HC) with the D(2/3) antagonist and agonist PET radiotracers [(11) C]raclopride and [(11) C]NPA. METHODS:[(11) C]raclopride and [(11) C]NPA binding potential (BP) (BP(ND) ) in the striatum were measured with kinetic analysis using the arterial input function. The available fraction of D(2/3 HIGH) receptors, i.e., % R(HIGH) available = D(2/3 HIGH) /(D(2/3 HIGH) + D(2/3 LOW) ) was then computed as the ratio of [(11) C]NPABP(ND) /[(11) C]racloprideBP(ND) . RESULTS: No differences in striatal [(11) C]NPABP(ND) (HC = 1.00 ± 0.17; CD = 0.97 ± 0.17, P = 0.67) or available % R(HIGH) (HC = 39% ± 5%; CD = 41% ± 5%, P = 0.50) was observed between cocaine abusers and matched controls. CONCLUSIONS: The results of this [(11) C]NPA PET study do not support alterations in D(2/3 HIGH) binding in the striatum in cocaine dependence.
Authors: N D Volkow; J S Fowler; A P Wolf; D Schlyer; C Y Shiue; R Alpert; S L Dewey; J Logan; B Bendriem; D Christman Journal: Am J Psychiatry Date: 1990-06 Impact factor: 18.112
Authors: O Mawlawi; D Martinez; M Slifstein; A Broft; R Chatterjee; D R Hwang; Y Huang; N Simpson; K Ngo; R Van Heertum; M Laruelle Journal: J Cereb Blood Flow Metab Date: 2001-09 Impact factor: 6.200
Authors: A Abi-Dargham; M Laruelle; J Seibyl; Z Rattner; R M Baldwin; S S Zoghbi; Y Zea-Ponce; J D Bremner; T M Hyde; D S Charney Journal: J Nucl Med Date: 1994-02 Impact factor: 10.057
Authors: Diana Martinez; Allegra Broft; Richard W Foltin; Mark Slifstein; Dah-Ren Hwang; Yiyun Huang; Audrey Perez; W Gordon Frankle; Thomas Cooper; Herbert D Kleber; Marian W Fischman; Marc Laruelle; W Gordon Frankel Journal: Neuropsychopharmacology Date: 2004-06 Impact factor: 7.853
Authors: Rajesh Narendran; Dah-Ren Hwang; Mark Slifstein; Peter S Talbot; David Erritzoe; Yiyun Huang; Thomas B Cooper; Diana Martinez; Lawrence S Kegeles; Anissa Abi-Dargham; Marc Laruelle Journal: Synapse Date: 2004-06-01 Impact factor: 2.562
Authors: David Matuskey; Patrick Worhunksy; Elizabeth Correa; Brian Pittman; Jean-Dominique Gallezot; Nabeel Nabulsi; Jim Ropchan; Venkatesh Sreeram; Rohit Gudepu; Edward Gaiser; Kelly Cosgrove; Yu-Shin Ding; Marc N Potenza; Yiyun Huang; Robert T Malison; Richard E Carson Journal: Neuroimage Date: 2016-02-11 Impact factor: 6.556
Authors: Doris E Payer; Arian Behzadi; Stephen J Kish; Sylvain Houle; Alan A Wilson; Pablo M Rusjan; Junchao Tong; Peter Selby; Tony P George; Tina McCluskey; Isabelle Boileau Journal: Neuropsychopharmacology Date: 2013-08-07 Impact factor: 7.853
Authors: Jan-Peter van Wieringen; Jan Booij; Vladimir Shalgunov; Philip Elsinga; Martin C Michel Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2012-12-09 Impact factor: 3.000
Authors: Christopher T Smith; Linh C Dang; Ronald L Cowan; Robert M Kessler; David H Zald Journal: Neuropharmacology Date: 2016-05-10 Impact factor: 5.250
Authors: David Matuskey; Edward C Gaiser; Jean-Dominique Gallezot; Gustavo A Angarita; Brian Pittman; Nabeel Nabulsi; Jim Ropchan; Paige MaCleod; Kelly P Cosgrove; Yu-Shin Ding; Marc N Potenza; Richard E Carson; Robert T Malison Journal: Drug Alcohol Depend Date: 2015-06-30 Impact factor: 4.492
Authors: Fernando Caravaggio; Lawrence S Kegeles; Alan A Wilson; Gary Remington; Carol Borlido; David C Mamo; Ariel Graff-Guerrero Journal: Synapse Date: 2016-07-11 Impact factor: 2.562
Authors: Vattoly J Majo; Matthew S Milak; Jaya Prabhakaran; Pratap Mali; Lyudmila Savenkova; Norman R Simpson; J John Mann; Ramin V Parsey; J S Dileep Kumar Journal: Bioorg Med Chem Date: 2013-06-12 Impact factor: 3.641
Authors: J Borg; S Cervenka; R Kuja-Halkola; G J Matheson; E G Jönsson; P Lichtenstein; S Henningsson; T Ichimiya; H Larsson; P Stenkrona; C Halldin; L Farde Journal: Mol Psychiatry Date: 2015-10-06 Impact factor: 15.992